拜耳(BAYRY)二季度Non-GAAP每股收益达0.95欧元胜预期

金吾财讯
Aug 04

金吾财讯 | 德国医药与农化巨头拜耳(BAYRY)发布2026财年第二季度财报。财报显示,公司二季度营收与盈利均超市场预期,并重申了经汇率调整后的2026全财年业绩指引。同时,得益于资本结构优化举措,公司显著下调全年净负债预期。数据显示,二季度公司Non-GAAP每股收益(EPS)达0.95欧元,超出市场预期0.20欧元;扣除特殊项目前的息税折旧及摊销前利润同比增长1.9%至21.44亿欧元。二季度实现营收108.7亿欧元,同比增长1.2%,较市场普遍预期高出1.8亿欧元。受相关法律诉讼及和解款项支付影响,二季度自由现金流降至-3.71亿欧元。拜耳重申2026全财年的核心业绩指标指引,并针对汇率影响与资产负债表进行积极修正:公司将2026年底的净金融负债预期从此前的320亿至330亿欧元下调至290亿至300亿欧元。这一调整主要源于此前宣布的交易——阿波罗旗下基金注资30亿欧元收购拜耳长效可逆避孕药业务新成立实体的少数非控制性股权。基于2026年6月30日的最新汇率预估,拜耳将全年集团销售额指引微调至447亿至467亿欧元(此前预估为445亿至465亿欧元),核心每股收益指引上调至4.20至4.70欧元(此前预估为4.10至4.60欧元)。市场分析认为,尽管诉讼开支对短期现金流构成一定侵蚀,但拜耳通过剥离非核心资产股权引入外部资本,正在加速修复负债表,核心业务的经营韧性也为全年业绩提供了有力支撑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10